| |
|
| Source: Company documents |
|
|
| Name
: |
Michael T. Flavin |
| Title
: |
Chairman of the Board, Chief Executive Officer |
| Since: |
1999 |
|
|
|
|
| Name
: |
John L. Flavin |
| Title
: |
President, Chief Financial Officer and Director |
| Since: |
06/2002 |
|
|
|
|
| Name
: |
Michael J. Cogan |
| Title
: |
Vice President and Controller |
| Since: |
10/2004 |
|
|
|
|
| Name
: |
Suseelan Pookote |
| Title
: |
Executive Vice President, Corporate Development |
| Since: |
|
|
|
|
|
| Name
: |
Ze-Qi Xu |
| Title
: |
Executive Vice President, Chief Scientific Officer |
| Since: |
10/2002 |
|
|
|
|
| Name
: |
David A. Eiznhamer |
| Title
: |
Vice President of Clinical Development |
| Since: |
2003 |
|
|
|
|
| Name
: |
Patrick W. Flavin |
| Title
: |
Chief Legal Counsel |
| Since: |
2004 |
|
|
|
|
|
|
|
| |
|
| Earnings
Release Dates : 7th May 2008 , 19th February 2008 , 14th November 2007 , 8th August 2007 |
|
 Audio |
|
|
| |
|
| |
|
| |
|
| |
| Busy Summer IPO Week Aug 08, 8:32 AM ET |
| Baidu.com jumps 350% Aug 08, 4:54 AM ET |
| Energy-related IPOs Dominate the Calendar Jul 24, 2:30 AM ET |
|
| |
Advanced Life Sciences Holdings, Inc.
The Company has developed a pipeline of clinical and preclinical product candidates from both in-licensing efforts and its own discovery programs in the areas of infectious disease, inflammation and oncology.
The Company’s most advanced product candidate, Cethromycin, is a novel ketolide antibiotic in Phase III clinical development for the treatment of respiratory tract infections. The Company is initially developing Cethromycin as a treatment for mild-to-moderate community acquired pneumonia.
|
| More... |
|
|
|
